Outcome and Disease Progression in NYHA Functional Class I and II Patients With Wild-Type Transthyretin Cardiomyopathy Treated With Tafamidis.

Sinigiani G;Sanna GD;Aimo A;Porcari A;Bonacchi G;De Michieli L;Milani P;Vergaro G;Tini G;Baldan M;Martire P;Beghini A;Tomasoni D;Palmiero G;Ossola P;Musca F;Zampieri M;Guidi Colombi G;Serenelli M;Cemin R;Iseppi M;Moretti M;Giacomin E;Negri F;Driussi M;Nuvolone M;Zanoletti M;Bianco M;Chinaglia A;Faro D;Ruotolo I;Longhi S;Monte IP;Lorenzoni G;Gregori D;Imazio M;Canepa M;Ricci F;Merlo M;Perazzolo Marra M;Limongelli G;Musumeci B;Perlini S;Cappelli F;Metra M;Corrado D;Sinagra G;Emdin M;Palladini G;Cipriani A.

2025